Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer Agrees To Hold Off On Price Increases After Speaking With Trump

By Catherine Sbeglia | July 11, 2018

Pfizer released a statement on Tuesday announcing that following a discussion with President Trump, the company will be deferring its price hikes that were effective July 1 to give Trump the chance to refine his plan to reduce drug prices and strengthen the U.S. healthcare system.

After Pfizer raised the prices of 100 of its products, the president called out the company in a Monday Tweet, saying, “Pfizer and others should be ashamed that they have raised drug prices for no reason.” 

Pfizer’s CEO Ian Read and Trump had an “extensive” discussion resulting in Pfizer agreeing to roll back prices to their pre-July levels. However, these prices are contingent on whether the Trump administration is successful in implementing their drug pricing blueprint by the end of the year. In an official statement, the drug company says it “will return these prices to their pre-July 1 levels as soon as technically possible, and the prices will remain in effect until the earlier of when the president’s blueprint goes into effect or the end of the year—whichever is sooner.”

Trump returned to Twitter to commend the company for its decision.

“Pfizer shares the President’s concern for patients and commitment to providing affordable access to the medicines they need,” said Read in an official statement released by the company. “The most fundamental way the biopharmaceutical industry creates value is by discovering innovative medicines that help people live longer, healthier, more productive lives. We have entered an exciting new era with scientific advances that will result in future breakthroughs and cures.”

Many have commented that they’ve yet to see much action on the part of the Trump administration when it comes to drug prices. However, the discussion between the president and Read demonstrates the potential of coming together and working towards share goals. Perhaps more discussion between members of the administration and drug companies will follow, and both sides can work to refine and implement a plan that works for the government, drug manufactures, and patients.

(Sources: Pfizer; Business Insider)

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards